1. Interval breast cancer is associated with other types of tumors
   Felix Grassmann et al, 2019, Nature Communications CrossRef
2. Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort
   Cody Ramin et al, 2023, Breast Cancer Research CrossRef
3. FRET mechanism between a fluorescent breast-cancer drug and photodynamic therapy sensitizers
   F. Lahoz et al, 2020, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy CrossRef
4. Opto-chemical and laser properties of FLTX1, a novel fluorescent tamoxifen derivative, and its potential applications in breast cancer photodynamic chemotherapy
   Mario Díaz et al, 2018, Optical Materials CrossRef
5. Protection against chemotherapy- and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals
   Yong-Qiang Liu et al, 2021, Phytomedicine CrossRef
6. Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial
   Flora Zagouri et al, 2022, British Journal of Cancer CrossRef
7. Colocalization of Estrogen Receptors with the Fluorescent Tamoxifen Derivative, FLTX1, Analyzed by Confocal Microscopy
   Araceli Morales et al, 2016, Estrogen Receptors CrossRef
8. Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials
   Evgeny Degtyarev et al, 2019, JCO Precision Oncology CrossRef
9. Biochemical Basis of Selective Accumulation and Targeted Delivery of Photosensitizers to Tumor Tissues
   Veronika I. Ivanova-Radkevich, 2022, Biochemistry (Moscow) CrossRef
10. FLTX2: A Novel Tamoxifen Derivative Endowed with Antiestrogenic, Fluorescent, and Photosensitizer Properties
    Mario Díaz et al, 2021, International Journal of Molecular Sciences CrossRef
11. Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis
    Jimmy LN Vo et al, 2014, OncoImmunology CrossRef
12. Second Primary Malignancies in Cancer Survivors
    Danielle M. Fournier et al, 2018, The Journal for Nurse Practitioners CrossRef
13. Uterine cancer in breast cancer survivors: a systematic review
    Akemi T. Wijayabahu et al, 2020, Breast Cancer Research and Treatment CrossRef
14. Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre
    Han Hsi Wong et al, 2024, Breast Cancer CrossRef
15. Gynaecological malignancies after breast cancer diagnosis: A population-based study
    MP Barretina-Ginesta et al, 2019, Clinical Journal of Obstetrics and Gynecology CrossRef
16. Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer
    Carolyn J. Kushner et al, 2018, Breast Cancer Research and Treatment CrossRef
17. Breast Cancer Survivorship Care: Targeting a Colorectal Cancer Education Intervention
    Sherri Homan et al, 2015, Journal of Personalized Medicine CrossRef
18. Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status
    Hyuna Sung et al, 2021, Cancer CrossRef
19. Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone Versus Hormone Therapy Alone or Combined Treatment for Low-Risk ER-Positive Early Stage Breast Cancer in Women Aged 65 Years and Older
    Matthew C. Ward et al, 2023, International Journal of Radiation Oncology*Biology*Physics CrossRef
20. Claudin 1 Promotes Migration and Increases Sensitivity to Tamoxifen and Anticancer Drugs in Luminal-like Human Breast Cancer Cells MCF7
    Bowen Zhou et al, 2015, Cancer Investigation CrossRef
21. Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis
    Isaac Allen et al, 2023, Breast Cancer Research CrossRef